

Supplementary Table 1 Breast cancer patients carrying a *BRCA1/2* germline mutation and treated with neoadjuvant chemotherapy: clinicopathological characteristics and response to treatment

ID	Age at diagnosis	Mutation type	Amino acid change	cT (cm)	cN	Histological type	Grade	ER status	Neoadjuvant chemotherapy	Tamoxifen*	Clinical response	Pathological response
AJ257	60.4	<i>BRCA2</i> : 6174delT	Stop 2003	8.0	1	Ductal	3	Neg	FACx3	No	Complete	Complete
J279	47.6	<i>BRCA1</i> : 4446C>T	R1443X	7.0	0	Undifferentiated	3	Neg	ACx4	Yes	Complete	Complete
J322	47.5	<i>BRCA2</i> : 8765delAG	Stop 2867	1.3	0	Ductal	2	Pos	ACx4 + Dx4	Yes	Complete†	Complete
1162	31.9	<i>BRCA1</i> : 4446C>T	R1443X	4.2	0	Undifferentiated	3	NA	ACx4	Yes	Complete	Complete
J007	43.4	<i>BRCA1</i> : 5382insC	Stop 1829	10.0	1	Ductal	3	Pos	ACx4	Yes	Complete	Incomplete
J415	50.6	<i>BRCA2</i> : 6174delT	Stop 2003	6.0	1	Ductal	3‡	Pos‡	ACx4	No	Complete	Incomplete
1108	32.2	<i>BRCA2</i> : 6085G>T	E1953X	7.0	1	Ductal	2	Neg‡	CEFx3	NA	Complete	Incomplete
99076	38.9	<i>BRCA1</i> : 185delAG	Stop 39	6.3	1	Ductal	3‡	Neg‡	FACx4	No	Complete	Incomplete
1236	49.9	<i>BRCA1</i> : 4446C>T	R1443X	6.0	0	Adenoca	2	NA	ACx4 + CMFx6	Yes	Complete‡	NE
98120	40.3	<i>BRCA1</i> : 4446C>T	R1443X	2.0	0	Ductal	3	Neg	FACx4	No	Complete	NE
1134	42.2	<i>BRCA1</i> : 4446C>T	R1443X	3.0	1	Ductal	2	Neg‡	ACx4 + Dx4	Yes	Partial‡	Incomplete

A, doxorubicin (Adriamycin®); adenoca, adenocarcinoma; C, cyclophosphamide; cN, clinical axillary lymph node status; cT, clinical tumour size; D, docetaxel (Taxotere®); E, epirubicin; ER, oestrogen receptor; F, 5-fluorouracil; M, methotrexate; NA, not available; NE, not evaluable; Neg, negative; Pos, positive.

*Concomitant administration with the neoadjuvant chemotherapy.

†Evaluated after four cycles of chemotherapy.

‡Evaluated after the neoadjuvant chemotherapy (at the time of surgery).